Reviewing Aprea Therapeutics (NASDAQ:APRE) & Oncobiologics (NASDAQ:OTLK)

Oncobiologics (NASDAQ:OTLK) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Oncobiologics and Aprea Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	2	2	0	2.20
Aprea Therapeutics	1	1	4	0	2.50

Oncobiologics currently has a consensus price target of $5.20, suggesting a potential upside of 954.77%. Aprea Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 426.02%. Given Oncobiologics’ higher possible upside, analysts plainly believe Oncobiologics is more favorable than Aprea Therapeutics.

Profitability

This table compares Oncobiologics and Aprea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Aprea Therapeutics	N/A	-47.60%	-40.97%

Risk & Volatility

Oncobiologics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.

Earnings and Valuation

This table compares Oncobiologics and Aprea Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35 million	88.90	-$62.42 million	($0.77)	-0.64
Aprea Therapeutics	$290,000.00	23.11	-$12.60 million	($1.08)	-0.49

Aprea Therapeutics has lower revenue, but higher earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Aprea Therapeutics beats Oncobiologics on 7 of the 12 factors compared between the two stocks.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.